$CLCS
Cell Source, Inc. Stock $clcs

$clcs Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-Q Financial Statement

#000149315223029915 Filed on August 23, 2023

Income Statement

Concept	2023 Q1	2022 Q1
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.077M	$573.7K
YoY Change	87.75%	-32.52%
% of Gross Profit
Research & Development	$338.5K	$464.5K
YoY Change	-27.13%	71.25%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$1.416M	$1.053M
YoY Change	34.47%	-6.13%
Operating Profit	-$1.416M	-$1.053M
YoY Change	34.47%	-6.13%
Interest Expense	-$276.0K	-$239.9K
YoY Change	15.06%	-40.57%
% of Operating Profit
Other Income/Expense, Net	-$276.0K	-$239.9K
YoY Change	15.05%	-40.53%
Pretax Income	-$1.692M	-$1.293M
YoY Change	30.87%	-15.23%
Income Tax
% Of Pretax Income
Net Earnings	-$1.692M	-$1.293M
YoY Change	30.86%	-15.2%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.05	-$0.05
Diluted Earnings Per Share	-$0.05	-$37.57K
COMMON SHARES
Basic Shares Outstanding	37.06M shares	34.40M shares
Diluted Shares Outstanding	37.06M shares	34.40M shares

Balance Sheet

Concept	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$133.0K	$132.0K
YoY Change	0.77%
Cash & Equivalents	$133.0K	$132.0K
Short-Term Investments
Other Short-Term Assets	$14.57K	$23.57K
YoY Change	-38.19%	-89.07%
Inventory
Prepaid Expenses	$84.84K	$121.2K
Receivables
Other Receivables
Total Short-Term Assets	$232.4K	$276.8K
YoY Change	-16.04%	28.33%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$0.00	-$1.00
YoY Change	-100.0%	-100.0%
TOTAL ASSETS
Total Short-Term Assets	$232.4K	$276.8K
Total Long-Term Assets	$0.00	-$1.00
Total Assets	$232.4K	$276.8K
YoY Change	-16.04%	-13.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.187M	$332.9K
YoY Change	256.67%	118.37%
Accrued Expenses	$4.161M	$918.6K
YoY Change	353.0%	-67.94%
Deferred Revenue
YoY Change
Short-Term Debt	$776.0K	$759.9K
YoY Change	2.11%	-16.77%
Long-Term Debt Due	$1.235M	$762.2K
YoY Change	62.03%	-83.64%
Total Short-Term Liabilities	$14.45M	$10.27M
YoY Change	40.67%	9.79%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.45M	$10.27M
Total Long-Term Liabilities	$0.00	$0.00
Total Liabilities	$14.45M	$10.27M
YoY Change	40.67%	9.79%
SHAREHOLDERS EQUITY
Retained Earnings	-$38.04M	-$32.47M
YoY Change	17.14%
Common Stock	$37.19K	$34.44K
YoY Change	7.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$14.22M	-$9.997M
YoY Change
Total Liabilities & Shareholders Equity	$232.4K	$276.8K
YoY Change	-16.04%	-13.17%

Cashflow Statement

Concept	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$1.692M	-$1.293M
YoY Change	30.86%	-15.2%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$310.0K	-$1.028M
YoY Change	-69.84%	-7.74%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$220.0K	$1.067M
YoY Change	-79.39%	9.75%
NET CHANGE
Cash From Operating Activities	-$310.0K	-$1.028M
Cash From Investing Activities
Cash From Financing Activities	$220.0K	$1.067M
Net Change In Cash	-$89.65K	$38.90K
YoY Change	-330.45%	-127.39%
FREE CASH FLOW
Cash From Operating Activities	-$310.0K	-$1.028M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001569340
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2022Q1	CLCS	Common Stock Based Compensation CommonStockBasedCompensation		usd
CY2022Q1	CLCS	Increase Decrease In Accrued Expenses Related Parties IncreaseDecreaseInAccruedExpensesRelatedParties		usd
CY2023Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
CY2023Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments		usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022Q1	CLCS	Conversion Of Accrued Expenses Into Note Principal ConversionOfAccruedExpensesIntoNotePrincipal		usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	000-55413
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Cell Source, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	32-0379665
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	57 West 57th Street
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 400
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10019
CY2023Q1	dei	City Area Code CityAreaCode	(646)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	416-7896
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	38195617	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	133012	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	222665	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	84837	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	164175	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	14571	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	23005	usd
CY2023Q1	us-gaap	Assets Assets	232420	usd
CY2022Q4	us-gaap	Assets Assets	409845	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1187192	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	680325	usd
CY2023Q1	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	876665	usd
CY2022Q4	us-gaap	Deferred Compensation Liability Current DeferredCompensationLiabilityCurrent	849898	usd
CY2023Q1	us-gaap	Dividends Payable Current DividendsPayableCurrent	302734	usd
CY2022Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent	5217	usd
CY2023Q1	us-gaap	Liabilities Liabilities	14452137	usd
CY2022Q4	us-gaap	Liabilities Liabilities	13043740	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37184505	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37184505	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	36081758	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	36081758	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	37185	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	36082	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	23778999	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	23674354	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-38037743	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-36346176	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-14219717	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-12633895	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	232420	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	409845	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1077049	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	573667	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	1415549	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	1052672	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1415549	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1052672	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-276018	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-239903	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1691567	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1292575	usd
CY2023Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	297517	usd
CY2022Q1	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	324917	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1989084	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1617492	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37059766	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37059766	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34400181	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34400181	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-12633895	usd
CY2023Q1	CLCS	Conversion Of Convertible Notes Payable And Accrued Interest Into Series C Convertible Preferred Stock And Common Stock ConversionOfConvertibleNotesPayableAndAccruedInterestIntoSeriesCConvertiblePreferredStockAndCommonStock	52060	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	-297517	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	21202	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	330000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1691567	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-14219717	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-9826135	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-9826135	usd
CY2022Q1	CLCS	Conversion Of Convertible Notes Payable And Accrued Interest Into Series C Convertible Preferred Stock And Common Stock ConversionOfConvertibleNotesPayableAndAccruedInterestIntoSeriesCConvertiblePreferredStockAndCommonStock	1433095	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Dividends In Excess Of Retained Earnings AdjustmentsToAdditionalPaidInCapitalDividendsInExcessOfRetainedEarnings	-324917	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	8043	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition	5372	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1292575	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-9997117	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-9997117	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1691567	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1292575	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	140248	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	73138	usd
CY2023Q1	CLCS	Noncash Interest Expense Warrants NoncashInterestExpenseWarrants	46131	usd
CY2022Q1	CLCS	Noncash Interest Expense Warrants NoncashInterestExpenseWarrants	-33609	usd
CY2023Q1	CLCS	Common Stock Based Compensation CommonStockBasedCompensation	330000	usd
CY2023Q1	CLCS	Warrants Based Compensation WarrantsBasedCompensation	-1095	usd
CY2022Q1	CLCS	Warrants Based Compensation WarrantsBasedCompensation	4960	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-79338	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-82514	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-8434	usd
CY2022Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	6652	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	506867	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	109818	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	139948	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-178453	usd
CY2023Q1	CLCS	Increase Decrease In Accrued Expenses Related Parties IncreaseDecreaseInAccruedExpensesRelatedParties	14500	usd
CY2023Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	77252	usd
CY2022Q1	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-80157	usd
CY2023Q1	CLCS	Increase Decrease In Accrued Interest Related Parties IncreaseDecreaseInAccruedInterestRelatedParties	104731	usd
CY2022Q1	CLCS	Increase Decrease In Accrued Interest Related Parties IncreaseDecreaseInAccruedInterestRelatedParties	213275	usd
CY2023Q1	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	27862	usd
CY2022Q1	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	12353	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-309613	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1028170	usd
CY2023Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	219960	usd
CY2022Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	95000	usd
CY2022Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	1000000	usd
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	27926	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	219960	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1067074	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-89653	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	38904	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	222665	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	93095	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	133012	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	131999	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	945	usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	30515	usd
CY2023Q1	CLCS	Issuance Of Warrants In Connection With Issuance Of Notes Payable IssuanceOfWarrantsInConnectionWithIssuanceOfNotesPayable	21202	usd
CY2022Q1	CLCS	Issuance Of Warrants In Connection With Issuance Of Notes Payable IssuanceOfWarrantsInConnectionWithIssuanceOfNotesPayable	8043	usd
CY2023Q1	CLCS	Accrual Of Warrant Obligations In Connection With Issuance Of Notes Payable AccrualOfWarrantObligationsInConnectionWithIssuanceOfNotesPayable	40167	usd
CY2022Q1	CLCS	Accrual Of Warrant Obligations In Connection With Issuance Of Notes Payable AccrualOfWarrantObligationsInConnectionWithIssuanceOfNotesPayable	114727	usd
CY2023Q1	CLCS	Conversion Of Accrued Expenses Into Note Principal ConversionOfAccruedExpensesIntoNotePrincipal	413018	usd
CY2023Q1	CLCS	Accrual Of Earned Preferred Stock Dividends AccrualOfEarnedPreferredStockDividends	-297517	usd
CY2022Q1	CLCS	Accrual Of Earned Preferred Stock Dividends AccrualOfEarnedPreferredStockDividends	-324917	usd
CY2023Q1	CLCS	Conversion Of Convertible Notes Payable And Accrued Interest Into Series C Preferred Stock And Common Stock ConversionOfConvertibleNotesPayableAndAccruedInterestIntoSeriesCPreferredStockAndCommonStock	52060	usd
CY2022Q1	CLCS	Conversion Of Convertible Notes Payable And Accrued Interest Into Series C Preferred Stock And Common Stock ConversionOfConvertibleNotesPayableAndAccruedInterestIntoSeriesCPreferredStockAndCommonStock	1433095	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1692000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-310000	usd
CY2023Q1	CLCS	Working Capital Surplus Deficiency WorkingCapitalSurplusDeficiency	14220000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-38038000	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	42632049	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	39196773	shares
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	563920	usd
CY2023Q1	CLCS	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Accrual Of Warrant Obligation FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccrualOfWarrantObligation	40167	usd
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	-47226	usd
CY2023Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	556861	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	463650	usd
CY2022Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease	33197	usd
CY2022Q1	CLCS	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Accrual Of Warrant Obligation FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityAccrualOfWarrantObligation	114727	usd
CY2022Q1	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	611574	usd
CY2023Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	154495	shares
CY2022	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	154495	shares
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	50983	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	50983	usd
CY2023Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.33
CY2022Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.33
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	328905	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4960	usd
CY2019Q4	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	267680	usd
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	146912	usd
CY2022	CLCS	Remaining Amount Due RemainingAmountDue	106000	usd
CY2023Q2	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	68000	usd
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	360000	shares

Files In Submission

Name	View Source	Status
0001493152-23-029915-index-headers.html	Edgar Link	pending
0001493152-23-029915-index.html	Edgar Link	pending
0001493152-23-029915.txt	Edgar Link	pending
0001493152-23-029915-xbrl.zip	Edgar Link	pending
clcs-20230331.xsd	Edgar Link	pending
ex31.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
clcs-20230331_cal.xml	Edgar Link	unprocessable
clcs-20230331_def.xml	Edgar Link	unprocessable
clcs-20230331_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
clcs-20230331_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CLCS
Cell Source, Inc. Stock $clcs

2023 Q1 Form 10-Q Financial Statement

#000149315223029915 Filed on August 23, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLCS Cell Source, Inc. Stock $clcs

2023 Q1 Form 10-Q Financial Statement

#000149315223029915 Filed on August 23, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CLCS
Cell Source, Inc. Stock $clcs